Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7% efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-blinded, placebo-controlled trial in the United Kingdom. The protocol was amended to include a blinded crossover. Data to the end of the placebo-controlled phase are reported.
METHODS: Adults aged 18-84 years received 2 doses of NVX-CoV2373 or placebo (1:1) and were monitored for virologically confirmed mild, moderate, or severe COVID-19 (onset from 7 days after second vaccination). Participants who developed immunoglobulin G (IgG) against nucleocapsid protein but did not show symptomatic COVID-19 were considered asymptomatic. Secondary outcomes included anti-spike (S) IgG responses, wild-type virus neutralization, and T-cell responses.
RESULTS: Of 15 185 participants, 13 989 remained in the per-protocol efficacy population (6989 NVX-CoV2373, 7000 placebo). At a maximum of 7.5 months (median, 4.5) postvaccination, there were 24 cases of COVID-19 among NVX-CoV2373 recipients and 134 cases among placebo recipients, a vaccine efficacy of 82.7% (95% confidence interval [CI], 73.3%-88.8%). Vaccine efficacy was 100% (95% CI, 17.9%-100.0%) against severe disease and 76.3% (95% CI, 57.4%-86.8%) against asymptomatic disease. High anti-S and neutralization responses to vaccination were evident, together with S-protein-specific induction of interferon-γ secretion in peripheral blood T cells. Incidence of serious adverse events and adverse events of special interest were similar between groups.
CONCLUSIONS: A 2-dose regimen of NVX-CoV2373 conferred a high level of ongoing protection against asymptomatic, symptomatic, and severe COVID-19 through >6 months postvaccination. A gradual decrease of protection suggests that a booster may be indicated.
CLINICAL TRIALS REGISTRATION: EudraCT, 2020-004123-16.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 3 vom: 08. Feb., Seite 398-407 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.02.2023 Date Revised 20.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac803 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347257534 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347257534 | ||
| 003 | DE-627 | ||
| 005 | 20240320232839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac803 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM347257534 | ||
| 035 | |a (NLM)36210481 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Heath, Paul T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7% efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-blinded, placebo-controlled trial in the United Kingdom. The protocol was amended to include a blinded crossover. Data to the end of the placebo-controlled phase are reported | ||
| 520 | |a METHODS: Adults aged 18-84 years received 2 doses of NVX-CoV2373 or placebo (1:1) and were monitored for virologically confirmed mild, moderate, or severe COVID-19 (onset from 7 days after second vaccination). Participants who developed immunoglobulin G (IgG) against nucleocapsid protein but did not show symptomatic COVID-19 were considered asymptomatic. Secondary outcomes included anti-spike (S) IgG responses, wild-type virus neutralization, and T-cell responses | ||
| 520 | |a RESULTS: Of 15 185 participants, 13 989 remained in the per-protocol efficacy population (6989 NVX-CoV2373, 7000 placebo). At a maximum of 7.5 months (median, 4.5) postvaccination, there were 24 cases of COVID-19 among NVX-CoV2373 recipients and 134 cases among placebo recipients, a vaccine efficacy of 82.7% (95% confidence interval [CI], 73.3%-88.8%). Vaccine efficacy was 100% (95% CI, 17.9%-100.0%) against severe disease and 76.3% (95% CI, 57.4%-86.8%) against asymptomatic disease. High anti-S and neutralization responses to vaccination were evident, together with S-protein-specific induction of interferon-γ secretion in peripheral blood T cells. Incidence of serious adverse events and adverse events of special interest were similar between groups | ||
| 520 | |a CONCLUSIONS: A 2-dose regimen of NVX-CoV2373 conferred a high level of ongoing protection against asymptomatic, symptomatic, and severe COVID-19 through >6 months postvaccination. A gradual decrease of protection suggests that a booster may be indicated | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: EudraCT, 2020-004123-16 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a asymptomatic infection | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a vaccine efficacy | |
| 650 | 7 | |a NVX-CoV2373 adjuvated lipid nanoparticle |2 NLM | |
| 650 | 7 | |a 2SCD8Q63PF |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Galiza, Eva P |e verfasserin |4 aut | |
| 700 | 1 | |a Baxter, David Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Boffito, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Browne, Duncan |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Chadwick, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Cosgrove, Catherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Galloway, James |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Anna L |e verfasserin |4 aut | |
| 700 | 1 | |a Heer, Amardeep |e verfasserin |4 aut | |
| 700 | 1 | |a Higham, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Iyengar, Shalini |e verfasserin |4 aut | |
| 700 | 1 | |a Jeanes, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Kalra, Philip A |e verfasserin |4 aut | |
| 700 | 1 | |a Kyriakidou, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Bradley, Judy M |e verfasserin |4 aut | |
| 700 | 1 | |a Munthali, Chigomezgo |e verfasserin |4 aut | |
| 700 | 1 | |a Minassian, Angela M |e verfasserin |4 aut | |
| 700 | 1 | |a McGill, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Munsoor, Imrozia |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholls, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Osanlou, Orod |e verfasserin |4 aut | |
| 700 | 1 | |a Packham, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Pretswell, Carol H |e verfasserin |4 aut | |
| 700 | 1 | |a San Francisco Ramos, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Saralaya, Dinesh |e verfasserin |4 aut | |
| 700 | 1 | |a Sheridan, Ray P |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Soiza, Roy L |e verfasserin |4 aut | |
| 700 | 1 | |a Swift, Pauline A |e verfasserin |4 aut | |
| 700 | 1 | |a Thomson, Emma C |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Viljoen, Marianne Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Fries, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Iksung |e verfasserin |4 aut | |
| 700 | 1 | |a McKnight, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Glenn, Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Rivers, E Joy |e verfasserin |4 aut | |
| 700 | 1 | |a Robertson, Andreana |e verfasserin |4 aut | |
| 700 | 1 | |a Alves, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Toback, Seth |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 3 vom: 08. Feb., Seite 398-407 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:3 |g day:08 |g month:02 |g pages:398-407 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac803 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 3 |b 08 |c 02 |h 398-407 | ||